Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > COLUMN
COLUMN
-
Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
-
Why Market Mapping Is Critical to Your Organization
February 24, 2023
-
When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
-
Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
-
How to Succeed in Bad Times and Good
December 9, 2022
-
The Pros and Cons of Working from Home in 2022
November 25, 2022
-
Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
-
The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
-
Fairness, Not Diversity
August 26, 2022
-
Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
-
The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
-
Please Come Back to the Office!
June 24, 2022
-
Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
-
Tapping into One’s Ikigai by Working from Home
May 27, 2022
-
The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
-
Five Ways to Get Your New Hire on the Same Page
March 31, 2022
-
4 Things You Can Do to Overcome Zoom Overload
November 26, 2021
-
What Does a Great Boss Look Like?
October 29, 2021
-
What Is the Price of a Work-Life Balance?
September 24, 2021
-
Obituary: P. Reed Maurer
September 14, 2021
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…